nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Appendix
|
|
|
2001 |
45 |
1-3 |
p. I-XIV nvt p. |
artikel |
2 |
Assessment of teratogenic risk
|
Battino, Dina |
|
2001 |
45 |
1-3 |
p. 171-173 3 p. |
artikel |
3 |
Assessment of teratogenic risk design and status of the North American antiepileptic drug registry
|
Holmes, Lewis B |
|
2001 |
45 |
1-3 |
p. 175-176 2 p. |
artikel |
4 |
author index
|
|
|
2001 |
45 |
1-3 |
p. 177-178 2 p. |
artikel |
5 |
Cognitive and behavioural assessment in clinical trials: when should they be done?
|
Thompson, Pam |
|
2001 |
45 |
1-3 |
p. 159-161 3 p. |
artikel |
6 |
Cognitive and behavioural assessment in clinical trials: when should they be done?
|
Aldenkamp, Albert P. |
|
2001 |
45 |
1-3 |
p. 155-157 3 p. |
artikel |
7 |
Cognitive and behavioural assessments in clinical trials: what type of measure?
|
Baker, Gus A |
|
2001 |
45 |
1-3 |
p. 163-167 5 p. |
artikel |
8 |
Cognitive and behavioural assessments in clinical trials: what type of study? — What type of measure?
|
Gillham, Ruth |
|
2001 |
45 |
1-3 |
p. 169-170 2 p. |
artikel |
9 |
Comparative trials: equivalence and differences in clinical trials
|
Mattson, Richard H |
|
2001 |
45 |
1-3 |
p. 105-107 3 p. |
artikel |
10 |
contents
|
|
|
2001 |
45 |
1-3 |
p. 183-184 2 p. |
artikel |
11 |
Do we need any more new antiepileptic drugs?
|
Brodie, Martin J. |
|
2001 |
45 |
1-3 |
p. 3-6 4 p. |
artikel |
12 |
General discussion
|
Richens, Alan |
|
2001 |
45 |
1-3 |
p. 41- 1 p. |
artikel |
13 |
Instructions to authors
|
|
|
2001 |
45 |
1-3 |
p. 181-182 2 p. |
artikel |
14 |
Monotherapy comparative trials: equivalence and differences in clinical trials
|
Chadwick, David |
|
2001 |
45 |
1-3 |
p. 101-103 3 p. |
artikel |
15 |
Monotherapy comparative trials: placebos and suboptimal comparators
|
Chadwick, David |
|
2001 |
45 |
1-3 |
p. 97-99 3 p. |
artikel |
16 |
Monotherapy comparative trials: placebos and suboptimal comparators
|
Schwabe, Stefan |
|
2001 |
45 |
1-3 |
p. 93-96 4 p. |
artikel |
17 |
Monotherapy studies: conversion versus de novo
|
Baulac, Michel |
|
2001 |
45 |
1-3 |
p. 79-80 2 p. |
artikel |
18 |
Monotherapy trial design: conversion versus de novo
|
Kälviäinen, Reetta |
|
2001 |
45 |
1-3 |
p. 75-78 4 p. |
artikel |
19 |
Monotherapy trials: endpoints
|
Mattson, Richard H |
|
2001 |
45 |
1-3 |
p. 109-117 9 p. |
artikel |
20 |
Monotherapy trials: endpoints
|
Chadwick, David |
|
2001 |
45 |
1-3 |
p. 119- 1 p. |
artikel |
21 |
Monotherapy trials: endpoints
|
Whitehead, John |
|
2001 |
45 |
1-3 |
p. 121-122 2 p. |
artikel |
22 |
Monotherapy trials: prerequisite data
|
Ben-Menachem, Elinor |
|
2001 |
45 |
1-3 |
p. 65-66 2 p. |
artikel |
23 |
Monotherapy trials: prerequisite data
|
Brodie, Martin J. |
|
2001 |
45 |
1-3 |
p. 61-64 4 p. |
artikel |
24 |
Monotherapy trials: presurgical studies
|
Pledger, Gordon |
|
2001 |
45 |
1-3 |
p. 67-71 5 p. |
artikel |
25 |
Monotherapy trials: presurgical studies
|
Binnie, Colin D |
|
2001 |
45 |
1-3 |
p. 73-74 2 p. |
artikel |
26 |
Monotherapy trials: sequential design
|
Holdich, Tom |
|
2001 |
45 |
1-3 |
p. 89-91 3 p. |
artikel |
27 |
Monotherapy trials: sequential design
|
Whitehead, John |
|
2001 |
45 |
1-3 |
p. 81-87 7 p. |
artikel |
28 |
Preface
|
French, Jacqueline A. |
|
2001 |
45 |
1-3 |
p. 1- 1 p. |
artikel |
29 |
Proof of efficacy studies: endpoints
|
Johnson, Tony |
|
2001 |
45 |
1-3 |
p. 57-59 3 p. |
artikel |
30 |
Proof of efficacy trials: choosing the dose
|
Pledger, Gordon |
|
2001 |
45 |
1-3 |
p. 23-28 6 p. |
artikel |
31 |
Proof of efficacy trials: choosing the dose
|
Schwabe, Stefan |
|
2001 |
45 |
1-3 |
p. 29-30 2 p. |
artikel |
32 |
Proof of efficacy trials: cross-over versus parallel-group
|
Richens, Alan |
|
2001 |
45 |
1-3 |
p. 43-47 5 p. |
artikel |
33 |
Proof of efficacy trials: crossover versus parallel-group studies
|
Johnson, Tony |
|
2001 |
45 |
1-3 |
p. 49-51 3 p. |
artikel |
34 |
Proof of efficacy trials: endpoints
|
French, Jacqueline A. |
|
2001 |
45 |
1-3 |
p. 53-56 4 p. |
artikel |
35 |
Proof of efficacy trials: seizure types
|
Schmidt, Dieter |
|
2001 |
45 |
1-3 |
p. 35-36 2 p. |
artikel |
36 |
Proof of efficacy trials: seizure types
|
Ben-Menachem, Elinor |
|
2001 |
45 |
1-3 |
p. 31-34 4 p. |
artikel |
37 |
Proof of principle trials: EEG surrogate endpoints
|
Binnie, Colin |
|
2001 |
45 |
1-3 |
p. 7-11 5 p. |
artikel |
38 |
Proof of principle trials: EEG surrogate endpoints
|
Richens, Alan |
|
2001 |
45 |
1-3 |
p. 13-14 2 p. |
artikel |
39 |
Proof of principle trials: exploratory open studies
|
Schmidt, Dieter |
|
2001 |
45 |
1-3 |
p. 15-18 4 p. |
artikel |
40 |
Proof of principle trials: exploratory open studies
|
Pierce, Mark W |
|
2001 |
45 |
1-3 |
p. 19-21 3 p. |
artikel |
41 |
Seizure types and syndromes: lumping or splitting
|
Dulac, Olivier |
|
2001 |
45 |
1-3 |
p. 37-40 4 p. |
artikel |
42 |
Subject index
|
|
|
2001 |
45 |
1-3 |
p. 179- 1 p. |
artikel |
43 |
Trial duration and follow-up
|
Perucca, Emilio |
|
2001 |
45 |
1-3 |
p. 123-127 5 p. |
artikel |
44 |
Trial duration and follow-up
|
Pierce, Mark W |
|
2001 |
45 |
1-3 |
p. 129-131 3 p. |
artikel |
45 |
Trials in children
|
Cross, Helen |
|
2001 |
45 |
1-3 |
p. 139-140 2 p. |
artikel |
46 |
Trials in children
|
Besag, Frank M.C. |
|
2001 |
45 |
1-3 |
p. 137-138 2 p. |
artikel |
47 |
Trials in children
|
Amann, J.P. |
|
2001 |
45 |
1-3 |
p. 133-136 4 p. |
artikel |
48 |
Trials in the elderly
|
Perucca, Emilio |
|
2001 |
45 |
1-3 |
p. 149-151 3 p. |
artikel |
49 |
Trials in the elderly
|
Brodie, Martin |
|
2001 |
45 |
1-3 |
p. 153-154 2 p. |
artikel |
50 |
Trials in women
|
Battino, Dina |
|
2001 |
45 |
1-3 |
p. 141-145 5 p. |
artikel |
51 |
Trials in women
|
Perucca, Emilio |
|
2001 |
45 |
1-3 |
p. 147- 1 p. |
artikel |